Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Ates cash on hand is dropping 8-12 mill a quarter
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Comment by TheMadMonkon Jan 13, 2022 11:44am
257 Views
Post# 34312936

RE:RE:RE:RE:Ates cash on hand is dropping 8-12 mill a quarter

RE:RE:RE:RE:Ates cash on hand is dropping 8-12 mill a quarterHey Wounded, I'll have you know that my team of psychiatrists say that I am doing much better now.  I was being conservative on my $5 price target.  Provided that everything goes well with P2 and we as we start P3, I think that there will be excitement around this company again and the stock price will reflect that.  These shares were trading over $7 heading into an AME study, there is no reason to think that they can't get back there heading into an P3.  In February of 2024 there are 3.36 million warrants expiring at $7.50, I personally feel that these warrants will be in the money by then and they will be exercised raising another $25.2 million for the company or an additional 10 months working capital based on the current spending rate.  These are just some of the thoughts from the voices in my head, so take it for what it's worth. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities